Stockreport

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

Emergent Biosolutions, Inc.  (EBS) 
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm Check Earnings Report
US:NYSE Investor Relations: investors.emergentbiosolutions.com
PDF As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray [Read more]